REVIEW ARTICLE
Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity
内镜下减肥与代谢治疗:糖尿病与肥胖的另外一种管理方法
Shreya Chablaney,
Nikhil A. Kumta,
Shreya Chablaney
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
Search for more papers by this authorCorresponding Author
Nikhil A. Kumta
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
Correspondence
Nikhil A. Kumta, Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, One Gustave L. Levy Place, Box 1069, New York, NY 10029.
Email: [email protected]
Search for more papers by this authorShreya Chablaney,
Nikhil A. Kumta,
Shreya Chablaney
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
Search for more papers by this authorCorresponding Author
Nikhil A. Kumta
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
Correspondence
Nikhil A. Kumta, Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, One Gustave L. Levy Place, Box 1069, New York, NY 10029.
Email: [email protected]
Search for more papers by this authorFunding information: No funding received.
Abstract
enEndoscopic bariatric and metabolic therapies (EBMTs) have sparked significant interest as minimally invasive therapeutic options for weight loss. Although bariatric surgery remains an effective option for sustained weight loss and improvement in the metabolic syndrome, access and utilization are limited. Various EBMTs have been designed to emulate the physiologic effects of established surgical interventions, including space-occupying and non-space-occupying gastric therapies, gastric remodeling procedures, and small bowel therapies. This review discusses the safety and efficacy of available US Food and Drug Administration-approved minimally invasive endoscopic bariatric interventions, as well as those currently under investigation. In addition, the role of endoscopic revision after failed surgical intervention is discussed.
Abstract
zh内镜下减肥与代谢治疗(Endoscopic bariatric and metabolic therapies，EBMTs)是一种微创的减肥治疗方法，目前这种方法已经引起人们的极大兴趣。尽管减肥手术一直是一种有效的可以用来持续减肥与改善代谢综合征的方法，但是目前人们接触与使用这种方法却是有限的。已经设计了各种EBMTs，使用已有的外科干预措施，包括胃占位与非胃占位疗法、胃重建手术以及小肠疗法来模拟生理效应。本综述对目前已有的美国食品与药品监督管理局批准的内窥镜下微创减肥手术的安全性与有效性进行了讨论，除此之外也讨论了目前正处于研究阶段的微创减肥手术方法。另外，还讨论了外科干预失败后内镜下修正术的作用。
CONFLICTS OF INTEREST
NK is a consultant for Apollo Endosurgery, Boston Scientific, and Olympus. SC has no conflicts of interest to declare.
REFERENCES
- 1Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: 2011-2014. NCHS Data Brief. 2015; 219: 1-8.
- 2Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017; 376: 254-266.
- 3Wharton S, Serodio KJ, Kuk JL, Sivapalan N, Craik A, Aarts MA. Interest, views and perceived barriers to bariatric surgery in patients with morbid obesity. Clin Obes. 2016; 6: 154-160.
- 4Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017; 152: 1791-1801.
- 5Laing P, Pham T, Taylor LJ, Fang J. Filling the void: a review of intragastric balloons for obesity. Dig Dis Sci. 2017; 62: 1399-1408.
- 6Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity. 2016; 24: 1849-1853.
- 7Popov VB, Ou A, Schulman AR, Thompson CC. The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis. Am J Gastroenterol. 2017; 112: 429-439.
- 8Dayyeh BKA, Kumar N, Edmundowicz SA, Larsen M, Sullivan S, Thompson CC. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015; 82: 425-438.e5.
- 9Imaz I, Martínez-Cervell C, García-Álvarez EE, Sendra-Gutiérrez JM, González-Enríquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008; 18: 841-846.
- 10Dumonceau J-MM. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg. 2008; 18: 1611-1617.
- 11Yorke E, Switzer NJ, Reso A, et al. Intragastric balloon for management of severe obesity: a systematic review. Obes Surg. 2016; 26: 2248-2254.
- 12Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2515 patients. Obes Surg. 2005; 15: 1161-1164.
- 13 U.S. Food and Drug Administration (FDA). FDA summary of safety and effectiveness data (SSED). PMA 140008. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008B.pdf. Published August 2015. Accessed November 20, 2018.
- 14Mathus-Vliegen EMH. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008; 26: 40-44.
- 15Roman S, Napoléon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004; 14: 539-544.
- 16Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity for the REDUCE Pivotal Trial Investigators. Surg Obes Relat Dis. 2015; 11: 874-881.
- 17Agnihotri A, Xie A, Bartalos C, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018; 16: 1081-1088.e1.
- 18 U.S. Food and Drug Administration (FDA). FDA summary of safety and effectiveness data (SSED). PMA P160001. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160001b.pdf. Published September 2016. Accessed November 20, 2018.
- 19Coskun H, Bozkurt S. A case of asymptomatic fungal and bacterial colonization of an intragastric balloon. World J Gastroenterol. 2009; 15: 5751-5753.
- 20Hurt R, Frazier T, Mundi MS. Novel nonsurgical endoscopic approaches for the treatment of obesity. Nutr Clin Pract. 2017; 32: 493-501.
- 21MacHytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011; 21: 1499-1507.
- 22Brooks J, Srivastava ED, Mathus-Vliegen EMH. One-year adjustable intragastric balloons: results in 73 consecutive patients in the UK. Obes Surg. 2014; 24: 813-819.
- 23Machytka E, Gaur S, Chuttani R, et al. Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study. Endoscopy. 2017; 49: 154-160.
- 24Al-Subaie S, Khalifa S, Buhaimed W, Al-Rashidi S. A prospective pilot study of the efficacy and safety of Elipse intragastric balloon: a single-center, single-surgeon experience. Int J Surg. 2017; 48: 16-22.
- 25Alsabah S, Al Haddad E, Ekrouf S, Almulla A, Al-Subaie S, Al KM. The safety and efficacy of the procedureless intragastric balloon. Surg Obes Relat Dis. 2018; 14: 311-317.
- 26Ryou M, McQuaid KR, Thompson CC, et al. ASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management. J Gastrointest Surg. 2017; 86: 1-12.
- 27Sullivan S. Aspiration therapy for obesity. Gastrointest Endosc Clin North Am. 2017; 27: 277-288.
- 28Sullivan S, Stein R, Jonnalagadda S, Mullady D, Edmundowicz S. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013; 145: 1245-1252.
- 29Thompson CC, Dayyeh BKA, Kushner R, et al. Percutaneous gastrostomy device for the treatment of Class II and Class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2016; 112: 447-457.
- 30Forssell H, Norén E. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy. 2015; 47: 68-71.
- 31Lee PC, Dixon J. Medical devices for the treatment of obesity. Nat Rev Gastroenterol Hepatol. 2017; 14: 553-564.
- 32Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol. 2017; 15: 619-630.
- 33Neylan CJ, Dempsey DT, Tewksbury CM, Williams NNN, Dumon KR. Endoscopic treatments of obesity: a comprehensive review. Surg Obes Relat Dis. 2016; 12: 1108-1115.
- 34Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013; 78: 530-535.
- 35Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015; 47: 164-166.
- 36Lopez-Nava G, Galvão MP, Da Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy. 2015; 47: 449-452.
- 37Lopez-Nava G, Galvão MP, Bautista-Castaño I, Jimenez-Baños A, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty: how i do it? Obes Surg. 2015; 25: 1534-1538.
- 38Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017; 27: 2649-2655.
- 39Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017; 15: 37-43.e1.
- 40Sharaiha RZ, Kumta NA, Saumoy M, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol. 2017; 15: 504-510.
- 41Espinós JC, Turró R, Mata A, et al. Early experience with the Incisionless Operating Platform (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg. 2013; 23: 1375-1383.
- 42López-Nava G, Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015; 11: 861-865.
- 43Miller K, Turró R, Greve JW, Bakker CM, Buchwald JN, Espinós JC. MILEPOST Multicenter Randomized Controlled Trial: 12-month weight loss and satiety outcomes after pose vs medical therapy. Obes Surg. 2017; 27: 310-322.
- 44Espinós JC, Turró R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg. 2016; 26: 1081-1089.
- 45Sullivan S, Swain JM, Woodman G, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity. 2017; 25: 294-301.
- 46Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery vs intensive medical therapy for diabetes - 3-year outcomes. N Engl J Med. 2014; 370: 2002-2013.
- 47Koehestanie P, De Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JWM. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014; 260: 984-992.
- 48Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016; 18: 300-305.
- 49Zechmeister-Koss I, Huić M, Fischer S. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg. 2014; 24: 310-323.
- 50Betzel B, Koehestanie P, Aarts EO, et al. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc. 2015; 82: 845-852.
- 51Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc Other Interv Tech. 2011; 25: 3028-3033.
- 52Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc Other Interv Tech. 2015; 29: 3298-3303.
- 53Vargas EJ, Rizk M, Bazerbachi F, Abu Dayyeh BK. Medical devices for obesity treatment: endoscopic bariatric therapies. Med Clin North Am. 2018; 102: 149-163.
- 54Cherrington AD, Rajagopalan H, Maggs D, Devière J. Hydrothermal duodenal mucosal resurfacing: role in the treatment of metabolic disease. Gastrointest Endosc Clin North Am. 2017; 27: 299-311.
- 55Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016; 39: 2254-2261.
- 56Machytka E, Bužga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc. 2017; 86: 904-912.
- 57Abu Dayyeh BK, Lautz DB, Thompson CC. Gastrojejunal stoma diameter predicts weight regain after Roux-en-Y gastric bypass. Clin Gastroenterol Hepatol. 2011; 9: 228-233.
- 58Thompson CC, Chand B, Chen YK, et al. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y gastric bypass surgery. Gastroenterology. 2013; 145: 129-137.
- 59Kumar N, Thompson CC. Comparison of a superficial suturing device with a full-thickness suturing device for transoral outlet reduction (with videos). Gastrointest Endosc. 2014; 79: 984-989.
- 60Vargas EJ, Bazerbachi F, Rizk M, et al. Transoral outlet reduction with full thickness endoscopic suturing for weight regain after gastric bypass: a large multicenter international experience and meta-analysis. Surg Endosc. 2018; 32: 252-259.
- 61Kumar N, Thompson CC. Transoral outlet reduction for weight regain after gastric bypass: long-term follow-up. Gastrointest Endosc. 2016; 83: 776-779.
- 62Jirapinyo P, Kröner PT, Thompson CC. Purse-string transoral outlet reduction (TORe) is effective at inducing weight loss and improvement in metabolic comorbidities after Roux-en-Y gastric bypass. Endoscopy. 2018; 50: 371-377.
- 63Schulman AR, Kumar N, Thompson CC. Transoral outlet reduction: a comparison of purse-string with interrupted stitch technique. Gastrointest Endosc. 2018; 87: 1222-1228.
- 64Jirapinyo P, Slattery J, Ryan MB, Dayyeh BKA, Lautz DB, Thompson CC. Evaluation of an endoscopic suturing device for transoral outlet reduction in patients with weight regain following Roux-en-Y gastric bypass. Endoscopy. 2013; 45: 532-536.
Citing Literature
